TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7618619
Drug: Captopril (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (150 mg/day in 3 separate doses)
Study: 414272
Drug: Alcohol state
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol state (1.0 ml/kg)
Study: 31601250
Drug: Social group/provider
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social group/provider intervention (social group treatment plus training of healthcare providers in health communication about MRDT)
Study: 31601250
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual practice of provision of MRDT services by public primary healthcare providers and patent medicine vendors)
Study: 25491347
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc as zinc sulfate daily for 17 days
Study: 23663094
Drug: Licorice (1140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice (1140 mg/day)
Study: 23663094
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogen 0.312 mg/day and Medroxyprogesterone 2.5 mg/day
Study: 17918451
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine for liver protection
Study: 7928829
Drug: Nitrofurantoin modified
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin modified release (MR) 100 mg bd
Study: 7928829
Drug: Co-trimoxazole 960
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 960 mg bd
Study: 7928829
Drug: Trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 200 mg bd
Study: 27668546
Drug: Oxycodone DETERx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone DETERx (Xtampza ER) administered sprinkled onto soft foods or via enteral feeding tubes
Study: 27668546
Drug: Oxycodone DETERx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone DETERx (Xtampza ER)
Study: 23746376
Drug: eGFR ≤29
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≤29 mL/min/1.73 m²
Study: 10644899
Drug: Estradiol patches
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol patches (Estraderm TTS; 0.8 mg)
Study: 10644899
Drug: d-amphetamine (AMPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMPH; 10 mg p.o.)
Study: 30185583
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy alone
Study: 30185583
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy with non-invasive ventilation (NIV) sessions
Study: 26655425
Drug: Bendamustine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine plus rituximab (90 mg/m2 on days 1 and 2, rituximab 375 mg/m2 on day 1)
Study: 26655425
Drug: Fludarabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine plus rituximab (25 mg/m2 on days 1-3, rituximab 375 mg/m2 on day 1)
Study: 25001947
Drug: sublingual melatonin
Normalized name: Melatonin/Pyridoxine 2.5 MG-0.338 MG Sublingual Tablet [BASIC'S SUBLINGUAL MELATONIN WITH B6]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual melatonin 3 mg
Study: 25001947
Drug: sublingual melatonin
Normalized name: Melatonin/Pyridoxine 2.5 MG-0.338 MG Sublingual Tablet [BASIC'S SUBLINGUAL MELATONIN WITH B6]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual melatonin 10 mg
Study: 25001947
Drug: sublingual placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual placebo
Study: 20375422
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g of fish oil emulsion/kg infusion for 14 days
Study: 20375422
Drug: 0.05 g
Normalized name: TRETINOIN 0.05 g in 100 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 g of fish oil/kg oral capsules after infusion
Study: 20375422
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion (placebo) for 14 days
Study: 20375422
Drug: Paraffin wax
Normalized name: Paraffin Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin wax oral capsules (placebo) after infusion
Study: 18415808
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 microg daily, 6 months)
Study: 18415808
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg daily, 3 weeks)
Study: 10411559
Drug: Omeprazole (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (i.v. administration in therapeutic doses)
Study: 7480549
Drug: Adinazolam 15
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam 15 mg
Study: 7480549
Drug: Adinazolam 45
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam 45 mg
Study: 7480549
Drug: Alprazolam (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (high dose) vs Adinazolam (high dose)
Study: 7006345
Drug: Cinoxacin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin at a dosage of 500 mg b.i.d.
Study: 7006345
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid at a dosage of 1 g q.i.d.
Study: 26217089
Drug: Risk prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk prediction scoring model (based on age ≥ 40 years, total bilirubin ≥ 171 μmol/L, prothrombin activity 40%‐60%, hepatitis B virus DNA > 107 copies/mL)
Study: 23001540
Drug: Resinous extract
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resinous extract from Commiphora swynnertonii at 400 mg/kg bodyweight
Study: 23001540
Drug: Resinous extract
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resinous extract from Commiphora swynnertonii at 800 mg/kg bodyweight
Study: 23001540
Drug: Anticoccidial drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoccidial drug
Study: 21124045
Drug: Transtympanic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic steroid injection (4 courses of methylprednisolone after conventional treatment)
Study: 11439379
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid treatment
Study: 11372906
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care services
Study: 2890442
Drug: pancuronium 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.12 mg.kg‐1
Study: 2890442
Drug: vecuronium 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.12 mg.kg‐1
Study: 2890442
Drug: atracurium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.4 mg.kg‐1
Study: 2890442
Drug: pancuronium‐metocurine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium‐metocurine mixture (0.4 mg + 1.6 mg/ml): 1 ml/10 kg
Study: 27581680
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg/day)
Study: 21965490
Drug: Transmucosal herbal
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transmucosal herbal periodontal patch (THPP) for three days
Study: 21965490
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches (PP) for three days
Study: 19828907
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng supplementation (500 mg daily for 4 months)
Study: 16735951
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and testosterone therapy
Study: 16735951
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy (untreated postmenopausal women)
Study: 8085692
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy plus radiation therapy
Study: 8085692
Drug: Interferon combined
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon combined with psoralen plus ultraviolet A light therapy
Study: 8085692
Drug: Photopheresis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photopheresis therapy
Study: 8085692
Drug: Interleukin-2 fusion
Normalized name: Anti-fap/interleukin-2 fusion protein ro6874281
DrugBank: Simlukafusp alfa (DB16092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 fusion toxins and several antibody conjugates
Study: 30470147
Drug: Gaviscon Double
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Double Action liquid (20 ml)
Study: 25871803
Drug: Morphine exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine exposure
Study: 23323867
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of donor feces after an initial vancomycin regimen (500 mg orally four times per day for 4 days) followed by bowel lavage and subsequent infusion.
Study: 23323867
Drug: Standard vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard vancomycin regimen (500 mg orally four times per day for 14 days).
Study: 14709942
Drug: SRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRI treatment for 8 weeks
Study: 11309437
Drug: Isotretinoin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (30 mg/day) for 3 years
Study: 7875957
Drug: Protirelin tartrate
Normalized name: PROTIRELIN
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protirelin tartrate 4 mg/die i.m.
Study: 31638960
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1000 mg administered intravenously twice, just before surgery and 6 hours after)
Study: 31638960
Drug: Combined TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined TXA (1000 mg of intra-articular TXA for each knee plus intravenous TXA as above)
Study: 28577752
Drug: TR Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR Band hemostasis with 10 cc of air for 1.5 hours
Study: 28577752
Drug: TR Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR Band hemostasis with 13 cc of air for 4 hours
Study: 28577752
Drug: TR Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR Band hemostasis with 10 cc of air for 3 hours
Study: 28577752
Drug: TR Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR Band hemostasis with 10 cc of air for 2 hours
Study: 28577752
Drug: TR Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR Band hemostasis with less than 13 cc of air
Study: 21231926
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy plus pharmacotherapy (IPT)
Study: 21231926
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus clinical management (CM)
Study: 18436027
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 epinephrine buccal infiltration
Study: 19228214
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration with articaine
Study: 22694755
Drug: Steroid-free (SF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free (SF) immunosuppression
Study: 22694755
Drug: Steroid-based (SB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-based (SB) immunosuppression
Study: 12610738
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide (10(‐2) g/ml to 10(‐8) g/ml)
Study: 12610738
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 microg/day for 3 weeks)
Study: 12610738
Drug: Overall dose-cutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall dose-cutaneous response effect
Study: 527352
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg penbutolol twice daily
Study: 30680400
Drug: Garlicin Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlicin Capsules 1/time, 3 times/d combined with Kangfuxin liquid 10 mL gargle 3 times/d
Study: 30680400
Drug: Kangfuxin liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuxin liquid 10 mL gargle 3 times/d
Study: 30680400
Drug: Garlicin Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlicin Capsules combined with Kangfuxin liquid
Study: 18759524
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral metronidazole
Study: 8776693
Drug: Nonsurgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical therapy (n = 24)
Study: 6333298
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase followed by heparin
Study: 6333298
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with heparin
Study: 25154829
Drug: Re-treatment Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Re-treatment Rituximab (RR)
Study: 22525771
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose (Glu)
Study: 22525771
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of galactose (Gal)
Study: 16225492
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate 100 mg twice a day
Study: 16225492
Drug: Iron-polymaltose complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-polymaltose complex 200 mg once a day
Study: 16225492
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatments
Study: 12419719
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg*kg(‐1) orally 60 min preoperatively (Group I)
Study: 12419719
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg*kg(‐1) orally 90 min preoperatively (Group II)
Study: 10365010
Drug: Levobupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (0.25% w/v 50 ml)
Study: 10365010
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% w/v 50 ml)
Study: 7574352
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (5 ml containing 500 IU of thrombin) applied by spray in the area of axillary dissection
Study: 2340347
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of vincamine
Study: 2340347
Drug: Gastrointestinal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal absorption of vincamine dissolved in saliva
Study: 21305611
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge (PL)
Study: 22470104
Drug: DT cigarette
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DT cigarette administration
Study: 10634020
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with spontaneous breathing (Group 2)
Study: 7044655
Drug: High-dose-aspirin/dipyridamole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-aspirin/dipyridamole combination (990 mg/day aspirin and 225 mg/day dipyridamole)
Study: 7044655
Drug: Low-dose-aspirin/dipyridamole (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-aspirin/dipyridamole (330 mg/day aspirin and 225 mg/day dipyridamole)
Study: 7044655
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (990 mg/day)
Study: 26364263
Drug: Daily combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) immediately
Study: 24333493
Drug: Prasugrel 10-mg
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10-mg once-daily maintenance dose (with or without a 60-mg loading dose)
Study: 24333493
Drug: Ticagrelor (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (continued therapy)
Study: 22315052
Drug: Novel care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel care pathway including diagnosis of 'diseased' QoL and up to five standardised treatments for specific QoL defects
Study: 18571336
Drug: 3D radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D radiation therapy (n = 29)
Study: 18571336
Drug: 2D radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2D radiation therapy (n = 38)
Study: 17467138
Drug: Immersion in
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersion in 0.1% (w/v) thymol-distilled water solution (24h)
Study: 15965572
Drug: Device therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device therapies
Study: 9663818
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (slide show, weekly phone calls, calendar)
Study: 7937285
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg twice/day
Study: 26578074
Drug: 3-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day trimethoprim-sulfamethoxazole therapy
Study: 26578074
Drug: 10-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day trimethoprim-sulfamethoxazole therapy
Study: 24676964
Drug: C-MAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-MAP plus treatment as usual (TAU)
Study: 11856686
Drug: Eptifibatide (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (loading dose via intraarterial injection or IV)
Study: 11856686
Drug: Eptifibatide (intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (intraarterial loading dose)
Study: 11856686
Drug: Control (rt-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rt-PA and heparin only)
Study: 7478776
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg aerosolized furosemide
Study: 2303573
Drug: 10% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% potassium nitrate glycerine-based gel
Study: 2303573
Drug: glycerine gel
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycerine gel without potassium nitrate
Study: 2303573
Drug: no gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no gel and no treatment (control)
Study: 6995134
Drug: Indomethacin 15
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 15 mg t.i.d.
Study: 6995134
Drug: Indomethacin 35
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 35 mg t.i.d.
Study: 6995134
Drug: Non-treatment periods
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment periods
Study: 28490871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimized treatment)
Study: 26228884
Drug: Intraventricular rtPA
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular rtPA treatment
Study: 26228884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rtPA treatment)
Study: 19440955
Drug: Nurse-administered propofol-alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered propofol-alfentanil sedation (NAPS)
Study: 19126940
Drug: Oral Sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sildenafil for 12 weeks
Study: 1699982
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg twice daily)
Study: 68044
Drug: Aqueous ragweed
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous ragweed extract (mean cumulative dose of 11.7 microng antigen E, equivalent to 4,180 PNU)
Study: 68044
Drug: Aqueous ragweed
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous ragweed extract (mean dose of 31.2 microng antigen E, equivalent to 11,140 PNU)
Study: 30523765
Drug: Selu-metinib in
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selu-metinib in combination with dacarbazine
Study: 26970181
Drug: Low-dose moderate-intensity
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose moderate-intensity aerobic exercise (150 min·week(‐1))
Study: 26970181
Drug: High-dose moderate-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose moderate-intensity aerobic exercise (300 min·week(‐1))
Study: 20184577
Drug: UK-369,003 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003 100 mg modified release (MR)
Study: 20184577
Drug: UK-369,003 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003 40 mg immediate release (IR)